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Myasthenia gravis (MG) is caused by antibodies that react mainly with the acetylcholine receptor on the postsynaptic site of the
neuromuscular junction. A wide range of clinical presentations and associated features allow MG to be classiﬁed into subtypes
based on autoantibody status. Striational antibodies, which react with epitopes on the muscle proteins titin, ryanodine receptor
(RyR), and Kv1.4, are frequently found in MG patients with late-onset and thymoma. Antititin and anti-RyR antibodies are
determined by enzyme-linked immunosorbent assay or immunoblot. More recently, a method for the detection of anti-Kv1.4
autoantibodies has become available, involving 12–15% of all MG patients. The presence of striational antibodies is associated
with more severe disease in all MG subgroups. Anti-Kv1.4 antibody is a useful marker for the potential development of lethal
autoimmune myocarditis and response to calcineurin inhibitors. Detection of striational antibodies provides more speciﬁc and
useful clinical information in MG patients.
1.Introduction
Acquired myasthenia gravis (MG) in an organ-speciﬁc
autoimmune disorder generally mediated by antiacetyl-
choline receptor (AChR) or less frequently by antimuscle-
speciﬁc tyrosine antibodies at the neuromuscular junction
[1]. Some MG patients have antibodies that bind in a
cross-striational pattern to skeletal and heart muscle tissue
sections. They were known as “striational antibodies.” These
autoantibodies recognize epitopes on skeletal muscle pro-
teins including myosin, actin, actinin, and ﬁlamin [2–5].
Particularly, three types of striational antibodies including
those to titin, ryanodine receptor (RyR), and Kv1.4 have
beeninvestigatedbymanyresearchers.Thedetectionofthese
three striational antibodies can provide more speciﬁc clinical
information and are associated with the subtypes of MG
patients. In this article, we describe the characteristics of
these three types of striational antibodies.
2.MolecularStructure
Titin is a giant protein (3000kD) abundantly in the skeletal
and cardiac sarcomere. Ninety percent of the titin mass is
contained in a repetitive structure of 2 diﬀerent 100-residue
repeats [6]. Anti-titin antibody was ﬁrst discovered in the
serum of MG patients by Aarli et al. in 1990 [7]. Autoan-
tibodies to titin are now determined by a commercially
available enzyme-linked immunosorbent assay (ELISA). The
mainimmunogenicregionoftitiniscalledmyastheniagravis
titin-30(MGT-30)andissituatedneartheA/I-bandjunction
[8–10].
RyR is a calcium release channel located in the sar-
coplasmic reticulum. There are two forms of RyR, skeletal
(RyR1) and cardiac (RyR2). The RyR is a protein containing
5035 amino acids with a molecular weight of 565kD. It
is composed of 4 homologous subunits that can build a
tetramer with a central channel [8]. Anti-RyR antibody was
ﬁrst identiﬁed by Mygland et al. in 1992 using western
blot for the presence of antibodies to the protein of the
sarcoplasmic reticulum from rabbit skeletal muscle [11].
Although cardiac and skeletal muscle RyRs are antigenically
diﬀerent, anti-RyR antibodies in MG patients cross-react
with both subtypes of the receptor [12]. Several epitopes in
both the N- and C-terminus of RyR1 sequence are identiﬁed
and used as antigenic peptide in ELISA.
Voltage-gated K channel (VGKC) consists of four trans-
membrane α-subunits that combine as homo- or heterote-
tramers. Kv1.4 is an α-subunit with a molecular weight of2 Autoimmune Diseases
73kD located mainly in the brain, peripheral nerves, and
skeletal and heart muscles. Anti-Kv1.4 antibody was ﬁrst
discoveredbyourgroupin2005usingaproteinimmunopre-
cipitation assay using 35S-labeled rhabdomyosarcoma (RD)
cellular extracts [13]. We cannot detect anti-Kv1.4 antibody
by immunoblot or ELISA using Kv1.4 recombinant protein.
This ﬁnding suggests that conformational epitopes may be
necessary for the detection of anti-Kv1.4 antibody.
3.AntibodiesDetection
MG can be classiﬁed into several subtypes based on the
autoantibodies proﬁle [1, 8]. Striational antibodies are prin-
cipally detected only in the sera of MG patients, but not in
healthy or diseased controls. Striational antibodies are rarely
found in AChR antibody-negative MG. The seropositivity
of striational antibodies was diﬀerent in the examined
populations. Generally, anti-titin antibody is detected in 20–
40% of all MG patients, anti-RyR in 13–38%, and anti-
Kv1.4 in 12–15% [8, 14–19]. It is well known that striational
antibodies are associated with the late-onset MG subgroup.
The disease onset age is eldest in MG patients with anti-titin
antibodies and youngest in those with anti-Kv1.4 antibodies
[8, 14–19]. It is likely that the gender ratio is almost equal in
striational antibodies.
Anti-titin antibodies are closely associated with older-
onset MG, and 60–80% of MG patients at disease onset older
than 60 years have anti-titin antibodies [8, 14–17, 19]. Our
recentstudyshowedthat32%oflate-onsetMGcaseswithout
thymoma were positive for anti-titin antibodies when the
cutoﬀ age between early- and late-onset MG was deﬁned
as 50 years [20, 21]. In addition, there can be two or three
of striational antibodies in a single MG patient. When we
measuredanti-AChR,anti-titin,andanti-Kv1.4antibodiesin
209JapaneseMGpatients,wefound8MGpatientswhowere
positive for all three autoantibodies [19].
To date, anti-titin and anti-RyR antibodies have been
examined in manyMG patients in theUS,Europe, and Asian
countries. Since common characteristics of MG patients
with anti-titin and anti-RyR antibodies have been described,
the clinical picture may be common across diﬀerent ethnic
groups and immunogenetic backgrounds. On the other
hand, since anti-Kv1.4 antibodies were studied only in Japan,
further examination is necessary in Caucasian MG patients.
4. Immunopathogenesis
There is no evidence that striational antibodies can really
induce structural changes in skeletal muscle [8]. However,
striational antibodies potentially indicate the presence of a
pathological process that, in addition to the AChR antibody-
mediated NMJ transmission defect, inﬂuences the muscle
cell function of the patient.
Some immunological evidence including complement
activation by striational antibodies and T cell proliferative
response to MGT-30 have been reported [22–24]; however,
these results do not prove the existence of any pathogenic
role for striational antibodies in MG. The presence of
titin antibodies in patients with MG correlates with the
electromyographic evidence of myopathy [25]. Anti-titin
antibody is associated with HLA DR7 in Caucasian MG
patients [8, 15, 21]. DR3 and DR7 have opposing eﬀects
on MG phenotypes in Caucasians. DR3 has a positive
association with early-onset MG and a negative association
with late-onset MG, and DR7 has the opposite association
[1]. DR3 and DR7 are very rare in Japanese populations.
In contrast, DR9 and DR2 in Japanese MG patients have
similar associations to those of DR3 and DR7, respectively,
in Caucasian patients [20].
Anti-RyR antibodies cause allosteric inhibition of RyR
function in vitro, inhibiting Ca2+ release from the sarcoplas-
mic reticulum [26]. Some MG patients have been shown
to have impaired excitation-contraction (E-C) coupling in
addition to neuromuscular transmission failure [27, 28].
The mechanisms of E-C coupling are closely related to
RyR function, and anti-RyR antibody may inﬂuence muscle
contraction. In this regard, a 27-year-old MG patient, who
was positive for anti-RyR antibody, but not anti-AChR, was
proven to be impaired E-C coupling [29]. In addition to
anti-RyR antibody, autoantibodies against dihydropyridine
receptor or transient receptor potential canonical type 3,
whichhavefunctionalinteractionswithRyR1inCa2+ release,
were also detected in MG patients [30, 31].
On the other hand, antineuronal VGKC antibody is prin-
cipallydiﬀerentfromanti-Kv1.4antibody(muscularVGKC).
Autoantibodies to neuronal VGKC are known to be asso-
ciated with acquired neuromyotonia, Morvan’s syndrome,
and autoimmune nonparaneoplastic limbic encephalitis.
The sera of patients with these diseases mainly target the
Kv1 α-subunits: Kv1.1, Kv1.2, or Kv1.6. The expression
of these subunits that form Kv channels diﬀers between
the brain and muscle. Recently, the clinical spectrum of
neurologic manifestations associated with neuronal VGKC
autoimmunity has been expanding [32]. However, leucine-
rich, glioma-inactive protein 1 was identiﬁed as a novel
autoantigen in limbic encephalitis previously attributed to
neuronal VGKC [33].
5.Thymoma-Associated MG
Most patients with thymoma-associated MG (T-MG) dem-
onstrateanantibodyproﬁlewithabroadstriationalantibody
response [1, 8]. The presence of thymoma is thought to
worsen the prognosis of MG, as symptoms are usually severe
in these patients and are not signiﬁcantly improved by
thymectomy[34].Ofthe260MGpatientsinourinstitutions,
62 (24%) had thymoma. The onset age of the thymomatous
MG patient was 47 ± 12 years [19]. Bulbar involvement and
myasthenic crisis were more common in patients with T-MG
than in those without thymoma.
The frequencies of striational antibodies in T-MG pa-
tients are generally high. Many reports have shown that
anti-titin antibodies are detected in 49–95% of T-MG,
with anti-RyR found in 70–80% of cases and anti-Kv1.4
in 40–70% of cases [7, 8, 11–20]. A high frequency of
striational antibodies in T-MG contributes to severe MGAutoimmune Diseases 3
Figure 1: Electrocardiogram in myasthenia gravis patients with anti-Kv1.4 antibodies. (a) Ventricular tachycardia, (b) sick sinus syndrome,
and (c) complete atrial ventricular block.
symptoms. Titin and RyR epitopes have been identiﬁed in
thymoma tissue [35–38]. In addition, we also conﬁrmed
that Kv1.4 mRNA was detected in thymoma tissue [13].
It is generally believed that the aberrant immunization of
T-cell against autoantigens is promoted by the pathogenic
microenvironmentinsidethethymoma[1,8].IgGstriational
autoantibodies to titin are also produced by clonal thymic B
cells established from patients with T-MG [39]. In addition,
the autoantibodies for C-terminal regions in RyR1 are
frequently detected in T-MG and may contribute to muscle
dysfunction via the impairment of Ca2+ release [40]. Anti-
RyR antibodies are found in spontaneous thymoma model
rats[41].Clinically,thepresenceofstriationalantibodiesand
computed tomographic scans of the anterior mediastinum
show a similar sensitivity for thymoma in MG patients. The
presence of titin and RyR antibodies in a young patient with
MG strongly suggested the presence of a thymoma [8].
6. ClinicalPresentation
Thepresenceofstriationalantibodiesisassociatedwithmore
severe disease in all MG subgroups. Many studies clearly
demonstrated that disease tends to be more severe in MG
patients found to be positive for each striational antibody
than in those found to be negative [8, 13, 17, 18, 42–44].
When the disease severity is compared between diﬀerent
striational antibodies, MG patients with anti-Kv1.4 antibod-
ies show more severe symptoms than those with anti-titin
antibodies[19].Similarly,itisalsoreportedthatMGpatients
with anti-RyR antibodies have more severe manifestations
than those with anti-titin antibodies [18]. In anti-Kv1.4-
positive patients, the frequencies of bulbar involvement and
myasthenic crisis were 73% and 31%, respectively [19]. In
addition,patientswithanti-RyRantibodieshavehighratesof
bulbar, respiratory, and neck involvement at MG onset [18].4 Autoimmune Diseases
Table 1: Three types of striational antibodies in myasthenia gravis (MG).
Autoantigen Titin Ryanodine receptor Voltage-gated K channel (VGKC)
(RyR) Kv1.4
Molecular structure
Skeletal and cardiac
sarcomere RyR1: skeletal type Brain, nerve, skeletal, and heart
muscles
Giant protein (3000kD) RyR2: cardiac type Homo- or hetero-tetramers
Repetitive structure 565kD with 4 homologous
subunits One α-subunit (73kD)
Original report Aarli et al. 1990 [7] Mygland et al. 1992 [11] Suzuki et al. 2005 [13]
Antibodies detection
ELISA (commercially
available) ELISA, Western blot Immunoprecipitation assay
Myasthenia gravis titin-30
(MGT-30) near the
A/I-band junction
Epitopes in both RyR1 and
RyR2
35-S-labeled rabdomyosarcoma
cell
Sarcoplasmic reticulum
from rabbit skeletal muscle
N- and C-terminus of RyR1
sequence
Band at 70kD
Epidemiology
20–40% in all MG patients 13–38% in all MG patients 12–15% in all MG patients
60–80% in MG patients
older than 60 years Mean onset age: 57 years Mean onset age: 49 years
32% in nonthymoma MG
patients older than 50 years M:F= 1:1 M:F= 1:1
Immunopathogenesis
T cell proliferative response
to MGT-30 Complement activation Diﬀerent from neuronal VGKC
Complement activation
Inhibiting Ca2+ release
from sarcoplasmic
reticulum
QT prolongation on
electrocardiogram
Myopathy in
electromyogram
Autoantibodies to
dihydropyridine receptor
Association with DR7 in
Caucasians
or transient receptor
potential canonical type-3
Inhibiting
excitation-contraction
coupling
Thymoma-associated
MG (T-MG)
49–95% in T-MG 70–80% in T-MG 40–70% in T-MG
Titin epitope expression RyR epitope expression Kv1.4 mRNA expression
Production from clonal
thymic B cells Diagnosis of thymoma
Diagnosis of thymoma
(younger than 50 years)
C-terminal regions in RyR1
as epitope
Clinical presentation
Association with severe MG More severe than anti-titin More severe with anti-titin
Concomitant with myositis
Bulbar, respiratory, and
neck involvement
Bulbar involvement and
myasthenic crisisMyocarditis
and/or myositis
Myocarditis and/or
myositis Lethal arrhythmias
Treatment and
management
Some late-onset MG with
ocular type
Early pharmacological
eﬀe c to ft a c r o l i m u s
Responder to calcineurin
inhibitors
poor prognosis in invasive
thymoma Sudden death
The other remarkable ﬁnding is the association between
striational antibodies and myositis and/or cardiomyositis
concomitant with MG [45, 46]. Autoimmune-mediated
myocarditis and/or myositis developed in a few patients
withMG,especiallythymoma-associatedMG.Inﬂammatory
myopathies did not only lead to the deterioration of muscu-
larweakness, but werealso the most serious complications in
the courses of MG patients. Since the mortality of MG itself
has dramatically decreased recently, cardiac involvement in
MG patients may be lethal. It is well known that myocarditisAutoimmune Diseases 5
is accompanied by thymoma-associated MG, known as
“Herzmyathenie”[46,47].Inthisregard,Evolietal.reported
that 7 of 50 T-MG cases suﬀered sudden deaths [34].
They speculated that some of these cases were aﬀected by
myocarditis, although autopsy studies were not performed.
Our survey in 5 Japanese institutions showed that of
924MG patients, 8 (0.9%) had inﬂammatory myopathies
[46]. The onset age of MG was 55.3 ± 10.3 years. All
patients showed severe symptoms with bulbar involvement
accompaniedbymyastheniccrisisin5andinvasivethymoma
in 4. Myocarditis was found in 3 patients and myositis
in 6. Myocarditis, developing 13–211 months after MG
onset, was characterized by heart failure and arrhythmias.
Histological ﬁndings of skeletal muscles showed CD8+ lym-
phocyte inﬁltration. Seven patients had at least one of three
striational autoantibodies. Immunomodulatory therapy was
required in all patients and was eﬀective for both MG and
inﬂammatory myopathies, except in one autopsy case.
We also conﬁrmed that some MG patients with anti-
Kv1.4 antibodies had a risk for lethal arrhythmias including
ventricular tachycardia, sick sinus syndrome, and complete
atrial ventricular block (Figure 1)[ 48, 49]. We emphasize
that special attention should be paid to MG patients with
anti-Kv1.4 antibodies. Although various Kv channels are
expressed in cardiac muscles and implicated in electrophysi-
ological function, the association between autoantibodies to
Kv channels and arrhythmias is not fully elucidated [50].
We are now investigating the mechanisms of the cardiac
involvement of Kv1.4 autoimmunity.
7. Treatment and Management
Since MG patients with striational antibodies have severe
symptoms, they usually require strong immunosuppressive
treatments. To avoid the many serious side eﬀects of corti-
costeroids, we prefer to use a combination of low or medium
doses of prednisone and other immunosuppressive agents.
In Japan, two calcineurin inhibitors (CNIs), cyclosporine
and tacrolimus, are widely used, since they are oﬃcially
approved as medications for MG treatment under the
national health insurance system in Japan. Since tacrolimus
acts as an enhancer of RyR-related Ca2+ release from the
sarcoplasmic reticulum, anti-RyR antibody is linked to the
early pharmacological eﬀects of tacrolimus [40]. To assess
the factors associated with the response to CNIs in MG,
we retrospectively analyzed the 6-month eﬀect of CNIs in
62MGpatients[51].Patientswhoachievedeithera ≥3-point
reduction in quantitative MG score or a ≥25% reduction in
thedailydoseofprednisolonewereregardedasrespondersto
CNIs. Anti-Kv1.4 antibody was proven to be associated with
being a responder to CNIs.
The long-term prognosis of MG patients with stria-
tional antibodies has not been fully elucidated. Side eﬀects
of immunotherapies including infection, diabetes, stroke,
ischemic heart disease, and cancers may also be more
important factors in mortality associated with MG than
the MG itself. The detection of striational antibodies may
be potentially useful for planning therapeutic strategy. The
presence of anti-RyR antibodies in T-MG and titin/RyR
in nonthymoma MG indicates a less favorable prognosis
[43]. However, some late-onset MG patients with anti-
titin antibodies are limited to the ocular form for long
periods. Further studies are necessary to prove the associ-
ation between the striational antibodies and the long-term
prognosis of MG.
8. Conclusion
We reviewed the characteristics of three types of striational
antibodies (Table 1). Although 20 years have passed since
the discovery of anti-titin antibodies in MG patient, the
detection of striational antibodies is not routinely tested in
the clinical management by all neurologist. Recently, several
therapies for MG have emerged, including rituximab and
antigen-speciﬁc apheresis whereas other treatments await
clariﬁcation of eﬃcacy and their role in MG [1]. The
treatment of MG should be individualized according to clin-
ical presentation or subtype, and requires a comprehensive
assessment of the patient’s functional impairment and the
eﬀect of MG on his or her daily life. The detection of
striational antibodies can provide information that is useful
for the classiﬁcation and management of MG patients.
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